

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2022**

	Note	Individual quarter		Cumulative quarter	
		Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
		30/09/2022 RM'000	30/09/2021 RM'000	30/09/2022 RM'000	30/09/2021 RM'000
<b>Revenue</b>		51,382	43,842	144,433	120,409
Cost of sales		(36,674)	(30,166)	(103,322)	(83,572)
<b>Gross profit</b>		14,708	13,676	41,111	36,837
Other operating income		95	692	1,018	1,174
Distribution costs		(2,962)	(3,412)	(9,265)	(9,383)
Administration expenses		(6,273)	(5,835)	(17,145)	(15,589)
Finance costs		(392)	(284)	(1,192)	(1,025)
<b>Profit before tax</b>		5,176	4,837	14,527	12,014
Tax expense	B5	(1,206)	(1,250)	(3,723)	(3,007)
<b>Profit for the financial period</b>		3,970	3,587	10,804	9,007
Other comprehensive income, net of tax		-	-	-	-
<b>Total comprehensive income</b>		3,970	3,587	10,804	9,007
<b>Profit attributable to:</b>					
Owners of the parent		3,204	3,163	9,679	8,131
Non-controlling interests		766	424	1,125	876
		3,970	3,587	10,804	9,007
<b>Total comprehensive income attributable to:</b>					
Owners of the parent		3,204	3,163	9,679	8,131
Non-controlling interests		766	424	1,125	876
		3,970	3,587	10,804	9,007
<b>Earnings per ordinary share attributable to owners of the parent:</b>					
- Basic (sen)	B15	1.45	1.57	4.48	4.05
- Diluted (sen)	B15	1.06	1.12	3.27	2.89

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2022**

	Note	As at 30/09/2022 RM'000	Audited As at 31/12/2021 RM'000
<b>Non-current asset</b>			
Property, plant and equipment		77,247	78,523
Right-of-use assets		10,747	11,141
Investment property		5,535	5,567
Biological assets		3,570	3,367
Goodwill		3,941	3,941
Other investment	B9	65	24
		<u>101,105</u>	<u>102,563</u>
<b>Current assets</b>			
Inventories		49,406	33,246
Trade and other receivables		33,408	38,578
Current tax assets		273	799
Cash and bank balances and short term funds		28,542	20,620
		<u>111,629</u>	<u>93,243</u>
<b>Total assets</b>		<u>212,734</u>	<u>195,806</u>
<b>Equity</b>			
Share capital		117,272	103,618
Reorganisation debit balance	B17	(59,489)	(59,489)
Retained earnings		94,702	87,236
<b>Total attributable to owners of the parent</b>		<u>152,485</u>	<u>131,365</u>
Non-controlling interests		8,913	7,788
<b>Total equity</b>		<u>161,398</u>	<u>139,153</u>
<b>Non-current liabilities</b>			
Borrowings	B10	22,444	25,698
Lease liabilities		-	177
Deferred tax liabilities		1,918	1,918
Deferred income		400	400
		<u>24,762</u>	<u>28,193</u>
<b>Current Liabilities</b>			
Trade and other payables		17,862	19,835
Borrowings	B10	7,596	7,087
Lease liabilities		263	315
Deferred income		4	14
Current tax liabilities		849	1,209
		<u>26,574</u>	<u>28,460</u>
<b>Total liabilities</b>		<u>51,336</u>	<u>56,653</u>
<b>Total equity and liabilities</b>		<u>212,734</u>	<u>195,806</u>

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT  
30 SEPTEMBER 2022 (CONTINUED)**

	<b>Note</b>	<b>As at 30/09/2022</b>	<b>Audited As at 31/12/2021</b>
<b>Net assets per share attributable to owners of the parent (RM)</b>	B16	0.69	0.65

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2022**

	<----- Attributable to owners of the parent ----->					
	<----- Non-distributable ----->		Distributable	Total attributable to owners of the parent	Non-controlling interest	Total equity
	Share capital	Reorganisation debit balance	Retained earnings	to owners of the parent	interest	Total equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
<b>Balance as at 1 January 2022</b>	103,618	(59,489)	87,236	131,365	7,788	139,153
Profit for the financial period	-	-	9,679	9,679	1,125	10,804
Other comprehensive income, net of tax	-	-	-	-	-	-
Total comprehensive income	-	-	9,679	9,679	1,125	10,804
Transactions with owners:						
Issuance of ordinary shares - private placement	13,458	-	-	13,458	-	13,458
Issuance of ordinary shares - exercise of warrants	196	-	-	196	-	196
Dividends paid	-	-	(2,213)	(2,213)	-	(2,213)
Total transactions with owners	13,654	-	(2,213)	11,441	-	11,441
<b>Balance as at 30 September 2022</b>	117,272	(59,489)	94,702	152,485	8,913	161,398
<b>Balance as at 1 January 2021</b>	103,618	(59,489)	79,985	124,114	6,537	130,651
Profit for the financial period	-	-	8,131	8,131	876	9,007
Other comprehensive income, net of tax	-	-	-	-	-	-
Total comprehensive income	-	-	8,131	8,131	876	9,007
Transactions with owners:						
Dividends paid	-	-	(2,008)	(2,008)	-	(2,008)
Total transactions with owners	-	-	(2,008)	(2,008)	-	(2,008)
<b>Balance as at 30 September 2021</b>	103,618	(59,489)	86,108	130,237	7,413	137,650

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2022**

	<b>Current year- to-date 30/09/2022 RM'000</b>	<b>Preceding year-to-date 30/09/2021 RM'000</b>
<b>Cash flows from operating activities</b>		
Profit before tax	14,527	12,014
Adjustments for:		
Depreciation	2,790	2,416
Inventories written off	368	524
Inventories written down	307	249
Impairment losses on trade receivables	148	360
Fair value loss on other investment	9	2
Interest expense	1,192	1,025
Loss on disposal of biological assets	30	147
Fair value changes on biological assets	(328)	(423)
Interest income	(90)	(133)
Unrealised loss/(gain) on foreign currency exchange	217	(187)
Operating profit before working capital changes	<u>19,170</u>	<u>15,994</u>
Changes in working capital:		
Inventories	(16,836)	(6,464)
Trade and other receivables	5,023	(3,863)
Trade and other payables	<u>(2,199)</u>	<u>1,045</u>
Cash generated from operations	5,158	6,712
Tax paid	<u>(3,557)</u>	<u>(2,382)</u>
Net cash from operating activities	<u>1,601</u>	<u>4,330</u>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(1,065)	(4,787)
Interest received	90	133
Acquisition of quoted shares	(50)	-
Purchase of biological assets	-	(599)
Proceeds from disposal of biological assets	<u>94</u>	<u>84</u>
Net cash used in investing activities	<u>(931)</u>	<u>(5,169)</u>
<b>Cash flows from financing activities</b>		
Net repayment of borrowings	(2,746)	(3,303)
Interest paid	(1,180)	(1,005)
Dividend paid	(2,213)	(2,008)
Payment of lease liabilities	(263)	(258)
Proceeds from issuance of shares	<u>13,654</u>	<u>-</u>
Net cash from/(used in) financing activities	<u>7,252</u>	<u>(6,574)</u>
Net increase/(decrease) in cash and cash equivalents	7,922	(7,413)
Cash and cash equivalents at beginning of financial period	<u>20,620</u>	<u>24,476</u>
Cash and cash equivalents at end of financial period	<u>28,542</u>	<u>17,063</u>

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2021 and the accompanying explanatory notes attached to these interim financial statements.

**A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS (“MFRS”) 134: INTERIM FINANCIAL REPORTING**

**A1. Basis of preparation**

The unaudited interim financial statements have been prepared in accordance with the requirements of MFRS 134 *Interim Financial Reporting* and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

These explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2021 and should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2021.

**A2. Significant accounting policies**

The significant accounting policies and methods of computation adopted for the interim financial statements are consistent with those adopted for the audited financial statements of the Group for the financial year ended 31 December 2021, except for the adoption of the following amendments to MFRSs during the financial year:

- Annual Improvements to MFRS Standards 2018 - 2020
- Amendments to MFRS 3 *Reference to the Conceptual Framework*
- Amendments to MFRS 116 *Property, Plant and Equipment - Proceeds before Intended Use*
- Amendments to MFRS 137 *Onerous Contracts - Cost of Fulfilling a Contract*

The adoption of the above amendments had no significant impact to the financial statements of the Group.

**A3. Auditors’ report**

There was no qualification to the audited financial statements of the Company and its subsidiaries for the financial year ended 31 December 2021.

**A4. Seasonal or cyclical factors**

The business operations of the Group were not materially affected by any seasonal and cyclical factors during the current quarter and financial year-to-date under review.

**A5. Unusual items affecting assets, liabilities, equity, net income or cash flows**

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group for the current quarter and financial year-to-date under review.

**A6. Changes in estimates**

There were no changes in estimates that have a material effect in the current quarter and financial year-to-date under review.

**A7. Debt and equity securities**

On 8 February 2022, Public Investment Bank Berhad had on behalf of the Board of Directors of the Company, announced that the Company proposes to undertake a proposed private placement of up to 28,120,300 new ordinary shares in the Company (“Placement Share(s)”), representing up to 10% of the enlarged number of issued shares in the Company (“Proposed Private Placement”).

The Company further announced on 14 February 2022 that Bursa Malaysia Securities Berhad (“Bursa Securities”) had, via its letter dated 14 February 2022, approved the listing and quotation of up to 28,120,300 Placement Shares to be issued pursuant to the Proposed Private Placement on the Main Market of Bursa Securities, subject to the conditions set out in Bursa Securities’ letter.

On 11 March 2022, the Company announced that the private placement of up to 28,120,300 new shares in the Company representing up to 10% of the enlarged number of issued shares of the Company (“Private Placement”) has been fixed at RM0.67 per Placement Share and will comprise up to 20,086,000 Placement Shares.

On 14 March 2022, the Company announced that the Private Placement has been completed following the listing of and quotation for 20,086,000 Placement Shares on the Main Market of Bursa Securities with effect from 9.00 a.m. on 14 March 2022. Pursuant to the Private Placement, the issued shares of the Company increased from 200,860,000 ordinary shares to 220,946,000 ordinary shares.

On 5 April 2022, the issued shares of the Company further increased from 220,946,000 ordinary shares to 221,226,000 ordinary shares pursuant to the issuance of 280,000 new ordinary shares arising from the exercise of 280,000 warrants by a warrant holder.

Save for the above, there were no other issuance, cancellation, repurchase, resale or repayment of debt and equity securities for the current quarter and financial year-to-date under review.

**A8. Dividend**

On 24 December 2021, the Board of Directors declared an interim single tier dividend of 1.0 sen per ordinary share totalling RM2.01 million in respect of the financial year ended 31 December 2021. The dividend had been accounted for in equity as an appropriation of retained earnings in the financial year ended 31 December 2021 and was paid on 25 January 2022 to shareholders registered at the close of business on 13 January 2022.

A final single tier dividend of 1.0 sen per ordinary share in respect of the financial year ended 31 December 2021 was approved by shareholders at the Company’s Annual General Meeting on 14 June 2022. The dividend was paid on 15 July 2022 and had been accounted for in equity as an appropriation of retained earnings in the financial year ending 31 December 2022.

**A9. Segmental information**

The Group’s operating segments are animal health products and equipment, food ingredients and others. These operating segments are required to be organised and managed separately according to the nature of products and services as well as specific expertise which require different business and marketing strategies. The segmental results are as follows:

	Individual quarter		Cumulative quarter	
	Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
	30/09/2022 RM'000	30/09/2021 RM'000	30/09/2022 RM'000	30/09/2021 RM'000
<b>Revenue</b>				
Animal health products and equipment	42,385	34,599	112,816	95,410
Food ingredients	7,920	7,587	26,085	19,558
Others	1,077	1,656	5,532	5,441
	<u>51,382</u>	<u>43,842</u>	<u>144,433</u>	<u>120,409</u>
<b>Profit before tax</b>				
Animal health products and equipment	5,067	3,103	12,929	9,233
Food ingredients	377	1,063	2,160	1,883
Others	(268)	671	(562)	898
	<u>5,176</u>	<u>4,837</u>	<u>14,527</u>	<u>12,014</u>

**A10. Property, plant and equipment**

(i) Acquisitions and disposals

There were no material acquisitions and disposals during the current quarter and financial year-to-date under review.

(ii) Impairment losses

There were no material impairment losses during the current quarter and financial year-to-date under review.

(iii) Valuation

The Group has not carried out any valuation on its property, plant and equipment during the current quarter and financial year-to-date under review.

**A11. Material events subsequent to the end of the quarter**

There were no material events subsequent to the end of the current quarter that have not been reflected in this interim financial report.

**A12. Changes in the composition of the Group**

There were no changes in the composition of the Group during the current quarter and financial year-to-date under review.

**A13. Contingent liabilities and contingent assets**

There were no contingent liabilities or contingent assets as at the date of this report.



**A14. Capital commitments**

The capital commitments of the Group as at the end of the quarter under review were as follows:

	RM'000
Approved and contracted for:	
- Construction of GMP-compliant plant in Nilai, Negeri Sembilan	2,495
- Machineries and equipment	1,110
- Milk processing plant	5,174
	<u>8,779</u>

**A15. Significant related party transactions**

The related party transactions during the current quarter and financial year-to-date under review are as follows:

	Individual quarter		Cumulative quarter	
	Current year quarter 30/09/2022 RM'000	Preceding year quarter 30/09/2021 RM'000	Current year-to-date 30/09/2022 RM'000	Preceding year-to-date 30/09/2021 RM'000
Nor Livestock Farm Sdn Bhd ("NLF") purchases feed from Nor Lazuli Nutrition ("NLN")	-	686	-	686
NLF purchases milk replacer from NLN	-	-	-	8
NLN purchases rice straw from NLF	-	4	-	30
One Lazuli Sdn Bhd ("OLSB") purchases feed from NLN	-	11	-	20
OLSB provides transportation services to NLN	-	3	-	12
NLF purchases anti- inflammatory medication, antibiotics, anti-parasitics and dairy milk machine parts from OLSB	-	80	-	117
NLN rents an office space from OLSB	-	3	-	9
NLF rents an office space from OLSB	-	1	-	2
NLF rents a farm land from Raja Mariam Binti Raja Rustam Shahrome ("RMRRS"), Dr Mai Lam @ Rosli Mai Lam ("ML") and Melissa Aini Mai ("MAM")	8	8	23	23
NLN rents a factory building from RMRRS, ML and MAM	8	8	23	23
OLSB rents an office space from RMRRS	45	45	135	135

**B. ADDITIONAL INFORMATION REQUIRED BY THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD**

**B1. Review of performance**

The Group recorded revenue of approximately RM51.38 million for the current quarter, an increase of approximately RM7.54 million compared to the revenue of approximately RM43.84 million in the preceding year's corresponding quarter. Revenue from animal health products and equipment increased by approximately RM7.79 million from approximately RM34.60 million in the preceding year's corresponding quarter to approximately RM42.39 million in the current quarter. Revenue from food ingredients increased by approximately RM0.33 million from approximately RM7.59 million in the preceding year's corresponding quarter to approximately RM7.92 million in the current quarter.

In line with the increase in revenue, the Group's profit before tax for the current quarter of approximately RM5.18 million was approximately RM0.34 million higher compared to the profit before tax of approximately RM4.84 million reported for the preceding year's corresponding quarter.

For the financial year-to-date under review, the Group recorded revenue of approximately RM144.43 million, an increase of approximately RM24.02 million compared to the revenue of approximately RM120.41 million in the corresponding period of the preceding year. Revenue from animal health products and equipment increased by approximately RM17.41 million from approximately RM95.41 million in the corresponding period of the preceding year to approximately RM112.82 million in the current period. Revenue from food ingredients increased by approximately RM6.53 million from approximately RM19.56 million in the preceding year's corresponding period to approximately RM26.09 million in the current period.

Consistent with the increase in revenue, the Group's profit before tax for the financial year-to-date under review of approximately RM14.53 million was approximately RM2.52 million higher compared to the profit before tax of approximately RM12.01 million reported for the preceding year's corresponding period.

**B2. Material changes in the quarterly results compared to the immediate preceding quarter**

The Group's revenue of approximately RM51.38 million for the current quarter was approximately RM4.55 million higher compared to the revenue of approximately RM46.83 million reported for the preceding quarter. The increase in revenue is mainly due to higher revenue from animal health products and equipment which increased by approximately RM6.17 million from approximately RM36.22 million in the preceding quarter to approximately RM42.39 million in the current quarter, but the increase was offset by decrease in revenue from food ingredients of approximately RM1.55 million from approximately RM9.47 million in the preceding quarter to approximately RM7.92 million in the current quarter.

In line with the increase in revenue, the Group's profit before tax for the current quarter of approximately RM5.18 million was approximately RM0.68 million higher compared to the profit before tax of approximately RM4.50 million reported for the preceding quarter.

**B3. Prospects**

The continued expansion of our operations through our future plans would provide a platform to grow and sustain our business. The Group will continue to focus on strengthening its production capabilities, product competitiveness and market position, while constantly seeking ways to mitigate the risks associated with its business. The Group will also continue to improve its internal controls and processes based on prudent management practices. In addition to improving on current operations, the Group is vigilant in identifying new business opportunities that has the potential for continuous growth and expansion.

In line with the projected growth of the Malaysian economy, the livestock industry is also anticipated to grow due to the corresponding growing Malaysian population resulting in the demand for meat as a source of protein to soar. The estimated increase in livestock in Malaysia is expected to result in correlating increase in demand for animal pharmaceutical and veterinary products, including animal feed to meet the rising needs. This is expected to augur well for the Group to ride on the growth trajectory in line with the government's endeavour to develop a sustainable livestock industry in the country for national food security. We are also anticipating growth in our dairy production business segment due to the projected uptrend in the local market. The production of milk in Malaysia was expected to increase in line with the government's aim to increase the country's fresh milk self-sufficiency level to 100% within five years and this will create abundant opportunities for the Group to capitalise on.

Based on the above, the Board is cautiously optimistic on the prospects and outlook of the Group. However, the Group will undertake a prudent approach in managing its business operations and aims to improve its efficiency and resilience in order to mitigate any risk that the Group may encounter moving forward.

**B4. Profit forecast**

The Group has not issued any profit forecast in any form of public documentation and announcement.

**B5. Tax expense**

	Individual quarter		Cumulative quarter	
	Current year quarter 30/09/2022 RM'000	Preceding year quarter 30/09/2021 RM'000	Current year-to-date 30/09/2022 RM'000	Preceding year-to-date 30/09/2021 RM'000
<b>Current tax</b>				
Current year	1,335	1,181	3,852	2,938
(Over)/under provision in prior years	(129)	69	(129)	69
	1,206	1,250	3,723	3,007

The effective tax rate of the Group for the current quarter of 23.30% was lower than the statutory tax rate of 24.00% mainly due to the reversal of over provision of taxes in prior years which amounted to approximately RM0.13 million. The effective tax rate of the Group for the financial year-to-date of 25.63% was higher than the statutory tax rate of 24.00% as certain subsidiaries were in loss making positions and that certain expenses were not allowable for tax purposes.

**B6. Notes to the Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income**

	Individual quarter		Cumulative quarter	
	Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
	30/09/2022	30/09/2021	30/09/2022	30/09/2021
	RM'000	RM'000	RM'000	RM'000
<b>Profit before tax is arrived at after charging / (crediting):</b>				
Depreciation	950	808	2,790	2,416
Inventories written off	260	506	368	524
Inventories written down	509	234	307	249
Impairment losses on trade receivables	56	120	148	360
Fair value changes on other investment	9	2	9	2
Interest expense	392	284	1,192	1,025
Loss on disposal of biological assets	6	-	30	147
Fair value changes on biological assets	(99)	(143)	(328)	(423)
Interest income	(37)	(49)	(90)	(133)
(Gain)/loss on foreign currency exchange	(430)	442	(516)	808

Save for the above, the other items as required under Appendix 9B Part A (16) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad are not applicable.

**B7. Status of corporate proposals**

There is no corporate proposal announced but not completed as at the date of this report.

**B8. Utilisation of proceeds**

The status of utilisation of proceeds of approximately RM13.46 million from the Company's Private Placement of 20,086,000 new ordinary shares at RM0.67 each as at the end of the quarter under review is as follows:

Details of the utilisation of proceeds	Proposed utilisation	Actual utilisation	Deviation	Balance unutilised	Estimated timeframe for utilisation
	RM'000	RM'000	RM'000	RM'000	
Establishment of a milk processing plant	7,500	(2,156)	-	5,344	Within 36 months
Marketing expenses	2,500	-	-	2,500	Within 36 months
Working capital	3,008	-	42 <sup>(1)</sup>	3,050	Within 12 months
Estimated expenses for the Private Placement	450	(408)	(42) <sup>(1)</sup>	-	Within 1 month
<b>Total</b>	<b>13,458</b>	<b>(2,564)</b>	<b>-</b>	<b>10,894</b>	

Note:

- (1) The actual expenses incurred for the Private Placement were less than the estimated expenses by approximately RM0.04 million due mainly to lower than expected incidental charges incurred in conjunction with the Private Placement. The surplus of funds for the payment of expenses for the Private Placement were adjusted to the amount allocated for working capital.

The utilisation of the proceeds as disclosed above should be read in conjunction with the Company's announcement dated 8 February 2022 and 11 February 2022.

**B9. Other investment**

	<b>As at 30/09/2022 RM'000</b>	<b>As at 31/12/2021 RM'000</b>
<b>Financial asset at fair value through profit or loss</b>		
Quoted shares in Malaysia	100	50
Less: Impairment loss	<u>(35)</u>	<u>(26)</u>
	<u>65</u>	<u>24</u>

**B10. Borrowings**

	<b>As at 30/09/2022 RM'000</b>	<b>As at 31/12/2021 RM'000</b>
<b>Non-current liabilities (secured)</b>		
Term loans	<u>22,444</u>	<u>25,698</u>
<b>Current liabilities (secured)</b>		
Bank overdrafts	3,016	2,508
Term loans	<u>4,580</u>	<u>4,579</u>
	<u>7,596</u>	<u>7,087</u>
<b>Total borrowings</b>	<u><u>30,040</u></u>	<u><u>32,785</u></u>

All borrowings are denominated in Ringgit Malaysia.

**B11. Material litigation**

There was no litigation which has a material effect on the financial position of the Group and the Board was not aware of any proceedings pending or of any fact likely to give rise to any proceedings as at the date of this report.

**B12. Dividend**

No dividend in respect of the financial year ending 31 December 2022 was declared or recommended for payment by the Company during the current quarter and financial year-to-date under review.

**B13. Derivative financial instruments**

The Group does not have any derivative financial instruments as at the end of the current quarter.

**B14. Gains/losses arising from fair value changes of financial liabilities**

There were no material gains or losses arising from fair value changes of financial liabilities during the current quarter and financial year-to-date under review.

**B15. Earnings per share**

	Individual quarter		Cumulative quarter	
	Current year quarter 30/09/2022	Preceding year quarter 30/09/2021	Current year-to-date 30/09/2022	Preceding year-to-date 30/09/2021
Profit attributable to owners of the parent (RM'000)	3,204	3,163	9,679	8,131
Weighted average number of ordinary shares in issue ('000)	221,226	200,860	216,126	200,860
Shares under warrant deemed to have been issued for no consideration ('000)	80,064	80,344	80,064	80,344
Weighted average number of ordinary shares for computing diluted earnings per share ('000)	301,290	281,204	296,190	281,204
Earnings per share				
- Basic (sen)	1.45	1.57	4.48	4.05
- Diluted (sen)	1.06	1.12	3.27	2.89

**B16. Net assets per share**

Net assets per share attributable to owners of the parent is arrived at by dividing the total equity attributable to owners of the parent at the end of the financial period by the number of ordinary shares in issue at the end of the financial period.

	As at 30/09/2022	As at 31/12/2021
Total equity attributable to owners of the parent (RM'000)	152,485	131,365
Number of ordinary shares in issue ('000)	221,226	200,860
Net assets per share attributable to owners of the parent (RM)	0.69	0.65

**B17. Reorganisation debit balance**

The reorganisation debit balance arose from the acquisition of RMM on 28 September 2016 based on the difference between the share capital issued by the Company and the share capital issued by RMM amounting to approximately RM59.49 million.